You are here

Phase III Clinical Trial for Virulizin Expanded

TORONTO, April 16 /CNW/ - Lorus Therapeutics Inc. ('Lorus') today announced that its lead immunotherapeutic drug Virulizin(R), for the treatment of advanced pancreatic cancer currently in a pivotal Phase III clinical trial, is being expanded to include approximately 50 clinical trial sites in North America and Latin America.

In addition to approximately 40 clinical sites and several new major cancer centers throughout the United States, the company has expanded the trial to 10 major oncology centers in Canada and Mexico. Participating Canadian centers include McGill University in Montreal and the Cross Cancer Center in Edmonton Alberta. In Mexico it will include the National Cancer Institute of Mexico and the National Medical Center in Mexico City, which are two of Latin America's leading oncology centers.

The Virulizin(R) Phase III clinical trial examines the drug in a first-line treatment setting in combination with gemcitabine, the only agent currently approved for the treatment of advanced pancreatic cancer. The same clinical trial also examines Virulizin(R) in combination with 5-flurouracil as a second line treatment option for patients that become resistant or intolerant to gemcitabine treatment.

"We are very pleased to be a part of the Virulizin(R) Phase III clinical trial of first-line treatment of advanced pancreatic cancer," said Dr. Richard Just, Scripps Cancer Center, San Diego, California. "Virulizin(R) shows promise as a well-tolerated immunotherapeutic drug for a devastating disease that is characterized by very few new treatment options."

Ongoing clinical study sites for Virulizin(R) are located throughout the U.S., such as New York, California, Florida, Michigan, Louisiana, and Ohio.

Details of the Phase III clinical study design and contact information have been posted on major oncology and pancreatic clinical trial web sites to facilitate awareness of the clinical trial in the health-care community.

"We are very impressed with the enthusiasm of our clinical investigators and study staff in our Phase III clinical program for Virulizin(R). Expansion of this trial to important oncology centers in Canada, Mexico, and the addition of new US sites is not only important for our clinical trial milestones, but is also central to our longer term global business strategy to have a strong presence in international markets, and the international oncology community," said Dr. Jim Wright, CEO, Lorus.

The US Food and Drug Administration awarded Virulizin(R) orphan drug status and fast track status for the treatment of pancreatic cancer. The drug has been approved in Mexico for the treatment of malignant melanoma, where it is commercially available through Mayne Pharma, Lorus' marketing partner in Latin America.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs